Repeat controlled human malaria infection of healthy UK adults with blood-stage
Plasmodium falciparum
controlled human malaria infection (CHMI)
human challenge model
malaria
malaria immunology
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
01
07
2022
accepted:
01
08
2022
entrez:
8
9
2022
pubmed:
9
9
2022
medline:
11
9
2022
Statut:
epublish
Résumé
In endemic settings it is known that natural malaria immunity is gradually acquired following repeated exposures. Here we sought to assess whether similar acquisition of blood-stage malaria immunity would occur following repeated parasite exposure by controlled human malaria infection (CHMI). We report the findings of repeat homologous blood-stage ClinicalTrials.gov, identifier NCT03906474, NCT02927145.
Identifiants
pubmed: 36072606
doi: 10.3389/fimmu.2022.984323
pmc: PMC9444061
doi:
Banques de données
ClinicalTrials.gov
['NCT03906474', 'NCT02927145']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
984323Informations de copyright
Copyright © 2022 Salkeld, Themistocleous, Barrett, Mitton, Rawlinson, Payne, Hou, Khozoee, Edwards, Nielsen, Sandoval, Bach, Nahrendorf, Ramon, Baker, Ramos-Lopez, Folegatti, Quinkert, Ellis, Poulton, Lawrie, Cho, Nugent, Spence, Silk, Draper and Minassian.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Adv Parasitol. 2013;81:223-55
pubmed: 23384625
Am J Trop Med Hyg. 1997 Oct;57(4):495-500
pubmed: 9347970
Proc Natl Acad Sci U S A. 2017 Mar 7;114(10):2711-2716
pubmed: 28223498
Clin Infect Dis. 2020 Dec 31;71(11):2849-2857
pubmed: 31782768
J Infect Dis. 2013 Jul 15;208(2):340-5
pubmed: 23570846
PLoS One. 2011;6(8):e21914
pubmed: 21887214
Med (N Y). 2021 Jun 11;2(6):701-719.e19
pubmed: 34223402
PLoS One. 2011;6(7):e22271
pubmed: 21799809
Nat Immunol. 2008 Jul;9(7):725-32
pubmed: 18563083
Lancet Infect Dis. 2018 Oct;18(10):e312-e322
pubmed: 29891332
PLoS One. 2013 Jun 18;8(6):e65960
pubmed: 23823332
Nat Med. 2016 Jun;22(6):614-23
pubmed: 27158907
J Infect Dis. 2016 Jun 1;213(11):1743-51
pubmed: 26908756
Lancet. 2002 Aug 24;360(9333):610-7
pubmed: 12241933
N Engl J Med. 2009 Jul 30;361(5):468-77
pubmed: 19641203
Am J Trop Med Hyg. 2004 Jun;70(6):642-4
pubmed: 15211006
Mol Ther. 2012 Dec;20(12):2355-68
pubmed: 23089736
Nat Commun. 2013;4:2836
pubmed: 24284865
Lancet. 2011 May 21;377(9779):1770-6
pubmed: 21514658
Malar J. 2015 Apr 07;14:143
pubmed: 25890156
Scand J Immunol. 1996 Feb;43(2):219-27
pubmed: 8633202
Immunology. 2014 Apr;141(4):628-44
pubmed: 24303947
PLoS One. 2014 Sep 25;9(9):e107903
pubmed: 25254500
Vaccine. 2006 Apr 5;24(15):2850-9
pubmed: 16434127
Am J Trop Med Hyg. 2018 Apr;98(4):1113-1119
pubmed: 29436349
Am J Trop Med Hyg. 1999 Jul;61(1 Suppl):20-35
pubmed: 10432042
Front Microbiol. 2016 Oct 13;7:1604
pubmed: 27790201
Proc Natl Acad Sci U S A. 2010 Apr 13;107(15):6958-63
pubmed: 20351286
J Infect Dis. 2016 Sep 1;214(5):772-81
pubmed: 27307573
Antimicrob Agents Chemother. 2005 Oct;49(10):4421-2
pubmed: 16189139
Front Pharmacol. 2014 May 30;5:125
pubmed: 24910614
Proc Natl Acad Sci U S A. 2013 May 7;110(19):7862-7
pubmed: 23599283
JCI Insight. 2021 Dec 8;6(23):
pubmed: 34609964
EBioMedicine. 2018 Oct;36:131-139
pubmed: 30243492